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STUDY PROTOCOL Open Access
A clinical and cost-effectiveness trial of a
parent group intervention to manage
challenging restricted and repetitive
behaviours in young children with autism
spectrum disorder: study protocol for a
randomised controlled trial
Victoria Grahame1*, Linda Dixon1, Sue Fletcher-Watson2, Deborah Garland3, Magdalena Glod4, Jane Goodwin4,
Zoe Grayson5, Saoirse Heron6, Emma Honey1, Rebecca Iversen6, Adetayo S. Kasim7, Ashleigh Kernohan8,
Ehsan Kharatikoopaei9, Ann Le Couteur4, Leila Mackie5, Ayesha Mathias10, Helen Probert11, Deborah Riby11,
Priyanka Rob4, Leanne Rogan1 , Sarah Thompson11, Luke Vale8, Eamonn Walls6, Elspeth Imogen Webb12,
Christopher Weetman10, Faye Wolstenhulme10, Ruth Wood10 and Jacqui Rodgers4
Abstract
Background: Restricted and repetitive behaviours vary greatly across the autism spectrum, and although not all are
problematic some can cause distress and interfere with learning and social opportunities. We have, alongside
parents, developed a parent group based intervention for families of young children with autism, which aims to
offer support to parents and carers; helping them to recognise, understand and learn how to respond to their
child’s challenging restricted repetitive behaviours.
Methods: The study is a clinical and cost-effectiveness, multi-site randomised controlled trial of the Managing
Repetitive Behaviours (MRB) parent group intervention versus a psychoeducation parent group Learning About
Autism (LAA) (n = 250; 125 intervention/125 psychoeducation; ~ 83/site) for parents of young children aged 3–9
years 11 months with a diagnosis of autism.
All analyses will be done under intention-to-treat principle. The primary outcome at 24 weeks will use generalised
estimating equation (GEE) to compare proportion of children with improved RRB between the MRB group and the LAA
group. The GEE model will account for the clustering of children by parent groups using exchangeable working
correlation. All secondary outcomes will be analysed in a similar way using appropriate distribution and link function.
(Continued on next page)
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The economic evaluation will be conducted from the perspective of both NHS costs and family access to local
community services. A ‘within trial’ cost-effectiveness analysis with results reported as the incremental cost per additional
child achieving at least the target improvement in CGI-I scale at 24 weeks.
Discussion: This is an efficacy trial to investigate the clinical and cost-effectiveness of a parent group based
intervention designed to help parents understand and manage their child’s challenging RRB. If found to be effective,
this intervention has the potential to improve the well-being of children and their families, reduce parental stress,
greatly enhance community participation and potential for learning, and improve longer-term outcomes.
Trial registration: Trial ID: ISRCTN15550611 Date registered: 07/08/2018. Sponsor and Monitor: Cumbria,
Northumberland, Tyne and Wear NHS Foundation Trust R&D Manager Lyndsey Dixon, Address: St Nicholas Hospital,
Jubliee Road, Gosforth, Newcastle upon Tyne NE3 3XT, lyndsey.dixon@cntw.nhs.uk, Tel: 0191 246 7222




Autism spectrum disorder (hereafter, ‘autism’) is a life-
long neurodevelopmental condition affecting 1–2% of
the population, with profound impact on diagnosed
individuals, families, and society [1, 2]. Restricted and re-
petitive behaviours (RRB) are one of two key behavioural
domains required for a diagnosis of autism [3]. They
include repetitive motor mannerisms, rigid adherence to
specific routines, highly circumscribed interests and ex-
treme responses to everyday sensory experiences. Some
RRBs are reported by autistic adults to be enjoyable,
functional and helpful. They may provide a basis for
friendship and can also build areas of strength, support-
ing skill development and yielding employment oppor-
tunities [4, 5]. However, RRB may also be outward signs
of anxiety or distress, deserving of attention and care
from others [6]. In some cases, RRB in children can have
a distressing and negative impact for the child and their
family members [7]. RRB can interfere with learning
opportunities, community participation, aspects of
health such as sleep and nutrition, and deplete child,
parent, and sibling wellbeing [8]. Examples observed by
practitioners include an elaborate and rigid bedtime
routine lasting 3 h or more, a restricted diet of only 5
different foods and a repetitive pattern of pinching
members of the public.
Here we use the term ‘challenging RRB’ to describe be-
haviours that fit the diagnostic description of a restricted
and repetitive behaviour and that cause significant
challenges for the child and in daily family life. A recent
meta-analysis indicates that parents of autistic children
experience higher levels of stress than parents of
children with other disabilities and that stress is highly
correlated with the presence of challenging RRB [9]. The
impact is greater if parents/carers are not able to access
appropriate advice and support [6]. Challenging RRB
may also incur direct risk of injury for the autistic child
[6]. They can take up large amounts of time, interfere
with the child’s ability to engage in everyday living activ-
ities (e.g. personal care, mealtimes) and reduce access to
learning [10–14]. Challenging RRBs are associated with
increased rates of disruptive behaviours and aggression
to others, which can further isolate the child and family
and contribute to negative stigma [15, 16].
Parents report they do not receive specific professional
advice on how to recognise or understand their child’s
challenging RRB [17]. It is therefore critical that parents
are supported to understand the different forms,
functions and impact of RRB. They need to be able to
distinguish possible underlying reasons for RRB and to
identify those RRB that have the potential for deleterious
impact on their child. They require evidence-based,
effective and efficient strategies to specifically address
challenging RRB. Such interventions, if found to be
effective, have the potential to improve the well-being of
autistic children and their families, reduce parental
stress, greatly enhance community participation and po-
tential for learning and improve longer-term outcomes.
In the UK, the National Service Framework for
Disabled Children and Young People and those with
Complex Health Needs highlights the potential impact
of care for parents of children with autism, and the need
for effective and efficient, evidence-based parent training
interventions [18]. The evidence base for the effective-
ness of parent-mediated interventions for young children
with autism has been reported [19]. However, to date,
most autism-specific early intervention programmes
focus on social communication and rarely consider
challenging repetitive behaviours despite this area being
a priority for parents [20–23]. Furthermore, a systematic
review on effectiveness of treatments for RRB in ASD
has established that strategies that involve understanding
the behaviour were promising but lacked a sufficient evi-
dence, as the majority of studies used single case designs
and focused solely on stereotypy [21]. Stereotypy is one
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specific type of RRB that is also less likely to be
perceived as challenging. A review of trial databases
(USNIH and UKCTG) indicates no current behavioural
intervention trial registered for RRB (2020). There is one
recently completed trial (completed Feb 2019) that aims
to use mobile technology to reduce stereotypy (repetitive
vocal and motor behaviours) in children with autism
and is thus not relevant to the current trial [24].
The Managing Repetitive Behaviours (MRB) parent
group intervention and study protocol were developed
jointly in partnership with parents of young children
with autism initially through two developmental parent
groups. The intervention was designed to help parents
recognise, understand and manage their child’s RRB
[25]. The development work was followed by a pilot
feasibility and acceptability randomised controlled trial
(RCT). The results of the feasibility and acceptability
pilot indicated that the MRB intervention was both
acceptable to parents and feasible to deliver through
routine clinical services. If effective, this intervention has
the potential to extend the range of early interventions
available to meet the needs of young children with aut-
ism and their families, ensuring best use of therapeutic
resources and reducing the risk that challenging RRB
persist with significant long-term consequences for the
child and family. However, before recommending that
this parent group intervention is included within local
community early intervention services, a fully powered
clinical- and cost-effectiveness RCT is required to rule
out harmful effects of the intervention and quantify any
benefit. This study is a phase 3 superiority trial, with a
parallel group design in which each family is randomised
1:1 to one of the two parent group interventions.
Methods and design
Study design
This study is a UK three-site, two-group RCT. After
consent families will be randomised at each site to
receive either the 8-week MRB parent group interven-
tion or the 8-week Learning About Autism (LAA) parent
group equivalent to best current practice and will act as
an attentional control for time and attention. Assess-
ments are administered on entry (baseline) to the trial,
at the end of the eight parent group sessions (10 weeks),
at 24 weeks primary endpoint and at the 52 weeks
follow-up.
Study aims
The aim of this study is to evaluate the clinical and cost-
effectiveness of the Managing Repetitive Behaviours
(MRB) parent group intervention for young children
with autism compared with a parent autism psychoedu-
cation group, at 10, 24 and 52 weeks follow-up.
The clinical effectiveness of this intervention will be
assessed by measuring whether children show an overall
improvement in global functioning (primary outcome) at
24 weeks (primary endpoint) after the MRB intervention
compared to the children whose parents had attended
the LAA group. There are a number of secondary
outcomes (measured at the end of the intervention and
at 24-week follow-up), these include whether (i) parents
increase their knowledge and skills in understanding and
managing their child’s challenging RRB; (ii) children
show a reduction in challenging RRB, and change in par-
ticipation in everyday activities, parent stress and impact
on family life; (iii) the intervention provides value for
money for the NHS; and (iv) these improvements are
maintained at 1 year from baseline.
We have carefully selected end of group and follow-up
(24 and 52 weeks) outcome measures to capture both
independent (blinded researcher), teacher and parent-
reported changes. These include blinded ratings of
improvement in child’s overall functioning (assessed
using Clinical Global Impressions–Improvement (CGI-
I)) and change in challenging RRB. Parent questionnaires
will also provide information on child RRB, child partici-
pation and daily living skills, parent stress, self-efficacy
and impact on family life. Parents will be aware of group
status but teachers and the primary outcome assessor
will be blind to group allocation.
We will evaluate maintenance of effect at the 52-week
follow-up appointment which will also allow us to investi-
gate any potential longer-term (downstream) impact on
child and family functioning (e.g. social participation).
Study setting
The MRB and the LAA parent groups will all take place
in community settings in different geographical locations
across the three UK sites: in Tyne and Wear, The
Lothians and Teesside. This is in line with the UK Na-
tional CAMHS Review (2008) [26], which indicated
young people and families want accessible services in
convenient places.
Managing Repetitive Behaviour (MRB) intervention
MRB is a manualised intervention designed to help par-
ents of young children with ASD to recognise, under-
stand and learn how to manage their child’s challenging
RRB. It is an 8-week manualised intervention designed
to be delivered by community-based professionals with
knowledge and experience of working with young chil-
dren with ASD and their families who have been trained
to deliver the MRB intervention. Each weekly session
lasts for approximately 2 h (total duration of group inter-
vention is ~ 16 h).
Each parent will be provided with a manual, related
weekly materials and individualised support to identify
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strategies to address challenging RRBs. ‘At home’ activ-
ities will be set each week for parents and children to
complete between sessions. The opportunity to identify
and practice new ideas outside of the clinic setting is
important for investigating how best to generalise the
approach into different settings for each child and
family.
Parents have the opportunities for individual support
and group learning. In weeks 2 and 7, they meet the
group leaders individually to select a target challenging
RRB to focus on during the group and to practise the
new skills they are learning, thus ensuring that strategies
are individually tailored for each child and are develop-
mentally appropriate.
Learning About Autism (LAA) parent group
LAA is an 8-week manualised parent psychoeducation
group that will act as an attentional control. LAA is
designed for parents of young children with autism and
focuses on understanding what autism is, and provides
support for parents of young children with autism. It is
designed to be run in the community with professionals
who have experience of working with young children
with autism and their families, and have been trained by
a UK-based autism charity, the National Autistic Society,
to deliver the intervention. Each weekly session lasts for
approximately 2 h (total duration of group intervention
is ~ 16 h).
The groups will offer parents and carers psychoeduca-
tion on understanding autism and what that means for
their individual child such as helping them understand
their child’s social communication difficulties and behav-
iour in different environments. It will also provide advice
and guidance on strategies and approaches for dealing
with behaviour problems in young children with ASD.
There will be opportunities for mutual support and shar-
ing of ideas with other parents. Thus increasing parents’
and carers’ understanding, confidence and responsive-
ness to their child’s patterns of communication and
interaction. This is equivalent to current best practice. It
will not include any specific information about the role
and functions of RRB, functional analysis and tailored
strategies to manage challenging RRB.
Recruitment and eligibility criteria
Families will be identified via local community National
Health Service (NHS) clinical services. Clinicians are
asked to introduce the study to families fitting the inclu-
sion criteria, discuss the study with them and if inter-
ested give them study packs. For some clinical services
where children may not be seen as frequently, postal
study packs will be sent to identified families. Interested
parents are asked to complete and return to the research
team an expression of interest form. The research team
will then contact parents they are interested in hearing
more about the study to arrange a face-to-face meeting
to discuss the study, what participation involves, answer
any questions they may have, and obtain written in-
formed consent.
Parents are eligible for study entry if their child meets
the following criteria: (1) aged 3–9 years 11 months at
the time of consent with a clinical diagnosis of autism or
autism spectrum disorder; (2) experience challenging
RRB. Parents themselves will have (1) sufficient spoken
and written English to provide written informed consent,
complete assessments, and participate in the interven-
tion; (2) are willing to be randomised and attend all
group sessions for the allocated arm of the study; and
(3) agree to maintain their child’s current medication re-
gime until the primary 24-week end point (clinician
changes to medication are permitted). Parents are not
eligible for study entry if their child meets the following
criteria: (1) no clinical diagnosis of autism or ASD; (2)
no challenging RRB (3) is currently taking part in an-
other parent group based intervention trial; or (4) has a
sibling already taking part in this study. Furthermore,
children of parents who have significant mental health
difficulties will not be eligible to participate. There will
be no special criteria for discontinuing or modifying al-
located interventions.
Training and fidelity
All parent group sessions in both arms of the trial will
be recorded, both to facilitate opportunities for supervi-
sion of the group leaders and to provide access to a
random sample of recorded sessions across all sites for
the independent evaluation of (i) the fidelity to the
delivery of the intervention and (ii) the therapeutic
competence of the individual group leaders’ delivery of
this manualised intervention. Fidelity will be formally
assessed by independent raters watching 10% of
randomly selected tapes and utilising the MRB Fidelity
Rating Scale as developed during the pilot feasibility and
acceptability study with adaptations for the content of
the LAA parent groups.
At the start of the research, the group leaders and site
clinical leads will attend a 1 day MRB training course
learning how to use the training manual and the mate-
rials for each 2 h weekly session and planning for home-
work tasks. Each group leader will learn about group
processes and gain skills to deliver the manualised inter-
vention in a participatory style, in combination with
strategies to personalise the programme for each parent.
The senior trainer (LD) alongside the chief investigator
(VG) will deliver the introductory training course. LD
will also visit each site as each new group is started. Fur-
thermore, to ensure the intervention is being delivered
to the families as intended with high fidelity to the
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manual, the senior trainer will alongside the local site
clinical lead, will undertake weekly supervision of group
leaders at each site. Group Leaders delivering the LAA
parent group will attend a 1-day training course specific-
ally designed for this study to ensure they are trained in
the skills needed to deliver the programme. This course
has been designed by the National Autistic Society and
will be delivered by DG.
Parent attendance at group sessions will be recorded
and monitored. Parents who miss a parent group session
will be contacted by a group leader to provide a brief
catch up of session and handouts for that session will be
posted out. Therapy compliance and receipt of other
interventions outside of the protocol will be monitored.
Avoidance of contamination
There will be separate clinical and research leads at each
site and separate training and supervision structures. Re-
searchers will be located separately from staff involved
in delivery of the MRB and LAA intervention. Research
interviews and assessments will be conducted mostly at
home visits, with the Autism Diagnostic Observation
Schedule-2 (ADOS-2) being undertaken at University
sites. All parents will be reminded prior to every contact
with research staff not to talk about group allocation.
Furthermore, we will also consider issues around poten-
tial contamination of the active attentional control LAA
group, by ensuring the LAA families are not on the case
load of the MRB intervention group leaders. The clinical
and research leads in the trial are experienced in studies
of this type and therefore able to take steps to discern
any potential risk of contamination bias and avoid it.
Baseline characterisation and outcome measures
Baseline characterisation measures
The following baseline measures will be collected:
 Demographics: a bespoke demographics tool has
been designed for the study.
 Autism Diagnostic Observation Schedule-2
(ADOS-2 [27];) is an observational assessment
undertaken by a trained researcher. It is a semi-
structured set of play and social communication
activities. ADOS-2 has demonstrated good inter-
rater reliability coefficients (Fleiss’ ĸ was .38
(range .19–.55) and Cohen’s ĸ was .69 (range .61–.76)
for all modules) in the clinical setting [28].
 Social Responsiveness Scale – Second Edition (SRS-
2 [29];): is a 65-item questionnaire measure of social
and communication features The pre-school and
school-age form has demonstrated adequate inter-
rater reliability across parent and teacher ratings.
Correlations were .77 and .61, respectively. There is
strong consistency across items on the SRS-2 school
age form which yielded a total reliability coefficient
of 0.95 [30].
Child outcome measures
Primary child outcome measure
 Clinical Global Impression-Improvement Scale
(CGI-I) [31] provides a standardised framework to
assess how much behaviour has improved or
worsened relative to the child’s baseline state using a
7-point scale. Research demonstrates that the
interclass correlation coefficient (ICC) between
therapist and patients rating of CGI-I was 0.65
indicating a moderate to high agreement between
the therapists CGI-I rating and patient’s perspective
on their condition [32].
Secondary child outcome measures
 Target Behaviour Vignette [33]. As part of the
baseline assessment, we require parents to undertake
a detailed semi-structured interview during which
they are required to identify two challenging RRB.
The protocol was developed by the Research Units
on Paediatric Psychopharmacology (RUPP) Autism
Network [33] and has demonstrated high levels of
agreement between expert raters. Arnold et al. [33]
reported an Intraclass Correlation Coefficient (ICC)
of 0.895 across a panel of five raters.
 Repetitive Behaviour Questionnaire - 2 (RBQ-2) [34]
The RBQ-2 is a 20-item questionnaire that measures
the frequency and intensity of RRB. RBQ-2
demonstrates good internal consistency for RRBs for
children with autism from 2 to 17 years. The
internal consistency was high for the Total RBQ-2
scale (Cronbach’s alpha = 86 for 20 items and .86 for
19 items) [35].
 Teacher Repetitive Behaviour Questionnaire 2
(Teacher RBQ-2) [36]. This is the corresponding
version of the parent RBQ-2 for completion by
teachers/teaching staff.
 Vineland Adaptive Behaviour Scales3 (VABS 3) [37].
The VABS 3 measures aspects of the child’s level of
adaptive functioning. VABS 3 has demonstrated
excellent internal consistency (Cronbach’s alpha 0.90
to 0.98) and content, construct, and concurrent
validity [37]. It has been used in numerous autism
studies.
Economic outcome measures
Primary economic outcome measure
 Incremental costs to achieve target difference in the
CGI-I at 24 weeks: The improvement scores from
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the CGI-I will be taken from each randomised arm
of the trial to inform the efficiency of the
intervention. A cost per incremental improvement
of CGI-I scale will be calculated in each pathway.
Secondary economic outcome measures
 Costs to the family: Cost to the family related to
MRB will be estimated. Resources questionnaires
and time and travel cost questionnaires are used to
aid the estimation of these costs. Total cost to the
family will be reported at 24 and 52 weeks.
 Incremental cost per QALY gained for the child:
The CHU9D [38] will be measured in both arms of
the trial to measure quality of life in relation to the
child. This will be measured at baseline, 24 and 52
weeks. The CHU9D proxy version will be used [38].
The CHU9D is a paediatric generic preference-based
measure of health-related quality of life that is
suitable for use in this particular patient group. This
measure has an acceptable level of internal
consistency (Cronbach alpha 0.781) [39]. Following
recommended practice parents/caregivers will be
asked to complete the CHU9D with the child at the
three time points. The responses from this
instrument will be used to create utility values,
which will be incorporated in QALY outcomes. This
will be expressed an in an average incremental costs
per QALY ratio for the children in each arm.
 QALYs for the caregiver: The EQ-5D-5L [40] will be
completed at baseline, 24 and 52 weeks by the
caregiver for the child. The EQ-5D-5L is a
standardised instrument for use as a measure of
health outcome. It is applicable to a wide range of
health conditions and treatments. The EQ-5D-5L
health questionnaire provides a simple descriptive
profile and a single index value for health status.
Initial psychometric properties of the 5-level EQ-5D
show that results for test-retest reliability for average
ICCs is 0.69 and VAS 0.51 indicating moderate
reliability [41]. The responses from this instrument
will be used to create utility values, which will be
used to create QALYs for the caregivers. This
outcome will be included as part of the cost
consequence analysis.
 Cost-consequences: A number of primary and
secondary clinical outcomes, quality of life effects for
the child and quality of life effects for the caregivers
will be used as outcomes for the cost-consequences
analysis.
 Use of the health care resources. Resources which
are used by the children will be measured using a
bespoke questionnaire. Parents/caregivers will be
asked to report the amount of times that their child
with ASD accesses certain services (e.g. GP or
outpatient appointments). This information will be
used to calculate the average cost of services for
each intervention.
Family outcome measures
 The Autism Family Experience Questionnaire
(AFEQ) [7]. This questionnaire measures broader
impact of an intervention on the family. Parent
(Cronbach’s alpha 0.85), Family (0.83), Child
Development (0.81), Child symptoms (0.79), AFEQ
total (0.92) [7].
Secondary parent outcome measures
 Parent self-efficacy [42]: This 15-item self-report
questionnaire that rates parental confidence in
managing behaviours on a 6-point scale ranging
from 0 (no confidence) to 5 (complete confidence).
 Autism Parenting Stress Index (APSI) [43]. This is a
measure of parenting stress specific to core and co-
occurring features of autism. The overall APSI scale
score demonstrates acceptable internal consistency
(Cronbach’s alpha 0.83) and test-retest stability
(Cronbach’s alpha 0.88) for parents of children with
autism [43]. Psychometric properties are good (e.g.
Cronbach’s alpha 0.83).
 Warwick-Edinburgh Mental Wellbeing Scale
(WEMWBS) [44] is a 14-item general population
screen of wellbeing and is psychometrically robust
with good internal consistency (Cronbach’s alpha
0.89) and test-retest reliability (ICC 0.83).
Participant timeline
Procedures
Data collection Baseline assessment and follow-up mea-
sures will be collected by RAs blinded to the outcome of
randomisation. RAs are trained to high levels of reliabil-
ity in all baseline characterisation and outcome measures
(see Table 1). All families will be allocated a unique
number that will be used to identify them on all paper
assessment forms throughout the trial. All data collected
on paper will be inputted into a data management sys-
tem for statistical analysis and all identifying data will be
stored securely separately. The Clinical Data Manage-
ment System (Elsevier’s MACRO) used for this trial is
fully compliant with all regulatory frameworks for
research of this nature. Patients cannot be identified
from eCRFs. The CI or delegated person will monitor
completeness and quality of data recording in eCRFs
and will correspond regularly with site PIs (or their
delegated team member) with the aim of capturing any
missing data where possible and ensuring continuous
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high quality of data. All study data will be treated in ac-
cordance with the latest Directive on Good Clinical
Practice (2005/28/EC).
Randomisation will be done through the Sealed Enve-
lope (www.sealedenvelope.com/) web-based randomisa-
tion service. Allocation will be by a minimisation scheme
instead of stratified randomisation to minimise sample
fragmentation because of the number of strata and to
avoid accidental imbalance between the MRB group and
the LAA group. Child level randomisation was preferred
controlling for child level characteristics that could affect
the primary outcome; treatment centre, age strata (under
5th birthday, 5th birthday and older), ethnicity, and gen-
der. Each case will be assigned a participant ID number
and treatment allocation emailed separately to the clinical
leads at each site. The clinical leads will inform the
families of the outcome of randomisation and this will also
be recorded in the participant’s NHS patient record.
We will collect information about severe adverse
events; as well as recording severe adverse events in a
standard format, we will include events of special
interest particularly relevant to this trial, such as signifi-
cant changes in family or school situation.
Data management
A Data Monitoring Committee (DMC) will meet once a
year to receive reports on recruitment and severe ad-
verse events. The DMC will evaluate the findings of the
internal pilot and submit report to NIHR, independently
chaired and with an independent statistician. Severe
adverse events, and actions taken, will be logged by the
senior trial manager (CTU) and a report presented to
DMC. The RA will discuss challenges with data
collection with research leads at each site and the core
research team. The RAs will be responsible for ongoing
review of data completeness and any concerns will be
discussed within the core research team, CTU and the
Sponsor as appropriate.
Primary, secondary and relevant exploratory and
sensitivity analyses of the data will take place by the trial
statistician and health economist in collaboration
with the Chief Investigator. The senior statistician
Table 1 Time points at which measures and data are collected
Procedure Screening Baseline Treatment phase Follow-up
Weeks 1–8 Week 10 Week 24 Week 52
Informed consent X





RBQ-2 X X X X
Teacher RBQ-2 X X X X
Measurement of the target behaviour vignette X X X X
VABS 3 X X
Parent self-efficacy questionnaire X X X X
Autism Parenting Stress Index X X X X
WEMWBS X X X
Autism Family Experience Questionnaire X X X
Proxy completed CHU9D X X X
EQ-5D-5L X X X
Resource use questionnaire X X X
Time and travel questionnaire X
Randomisation** X
Weekly intervention (MRB or Learning About Autism) X
*Child demographics to include child age, gender, type of nursery/school, diagnosis, current medications, additional diagnoses, ethnicity and previous
intervention exposure
*Parent demographics to include level of education, employment status, family structure, attendance at previous courses or interventions relating to children with
a diagnosis of ASD
**Randomisation to take place following completion of baseline assessment
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will independently reproduce the primary analyses
whilst still remaining blinded to the intervention
groups. The senior statistician will have an overview
of the entire analyses and will explicitly check the
statistical codes. Other members of the team (e.g.
the trial health economist) will also have access to
data and will undertake analysis as appropriate and
necessary. We have carefully considered the ethical
implications in relation to this type of parent group
intervention trial and there are no anticipated detri-
mental issues to participants. There are therefore no
planned interim analyses. Any arrangements for
other researchers in the general field to have access




We plan to approach approximately 325 families and ex-
pect to randomise 250 families (125 randomised to each
arm). Assuming 5% type I error, 90% power, 10% intra-
group correlation and equal allocation ratio, 224 families
(an average of 8 families per parent group) are required
to detect 20% improvement rate between the MRB inter-
vention and Learning About Autism group at 24 weeks.
Allowing for an attrition rate of 12%, 250 families will be
randomised. The 10% intra-cluster correlation was based
on review of group interventions in education trials [45].
Sample size was calculated in R using n4pros in CRTSize
package [46].
Analysis plan
A statistical analysis plan will be written and agreed by
the Trial Steering Committee and Data Monitoring
Committee before any analysis is undertaken. All statistical
analyses will be carried out using the latest version of R
software [46]. All analyses will be done in accordance with
intention-to-treat principle where all children and parent
outcomes are analysed as randomised. In accordance with
CONSORT statement for non-pharmacological interven-
tions, we will report all participant flow. Data will be sum-
marised by trial arm. N, Mean ± SD, (or median ± IQR if
data are skewed), Minimum and Maximum will summarise
continuous variables, whereas number and percentages will
be used to summarise categorical variables.
The analysis of the primary outcome at 24 weeks will
use generalised estimating equations with binomial
distribution and logit link. Exchangeable working
correlation will be used to account for the clustering of
children by parent groups. The continuous secondary
outcomes will first be analysed at 24 weeks using a
difference-in-difference model based on linear mixed ef-
fect model accounting for paired data (at baseline and at
24 weeks) per child and clustering of children by parent
groups. The same model will be applied to the data at
week 52, which will be analysed as longitudinal data in-
corporating data at baseline and 24 weeks. All binary or
categorical secondary outcomes will be analysed using
generalised estimating equations. We will also perform
subgroup analysis and safety analysis, sensitivity analysis
for missing data and assess the impact of the COVID-19
pandemic on primary and secondary outcomes.
Health economics
Economic evaluation
The economic evaluation will be carried out from the
perspective of the NHS and personal social services. A
cost-effectiveness analysis within trial which will com-
pare the costs to achieve the target mean difference in
the CGI-I in both the MRB and Learning About Autism
groups at 24 weeks. A cost-utility approach will also be
undertaken using the data from the CHU9D questionnaire
to synthesise QALYs for the children and compare the in-
terventions using an incremental costs per QALY approach.
To measure the benefits which would not be captured in
the metric of a QALY. Finally, a cost-consequence will be
used to compare costs and benefits from a wider perspec-
tive (for example the broader costs to families).
Measurement of effects
For the cost-effectiveness analysis, the effectiveness
measure will be based on the results from the primary
trial outcome; the target mean difference in the CGI-I.
The costs utility analysis will use the responses from
the CHU9D based on the proxy responses from child’s
caregiver. The CHU9D will be administered at baseline,
24 weeks and 52 weeks. This will measure the quality of
life of the child which will be converted into QALYs for
each child using the under the curve approach and an
average incremental cost per QALY in each randomised
arm will be calculated.
The caregiver will complete ED-5D-5L at baseline, 24
and 52 weeks. These responses will measure quality of
life in relation to the caregiver and will be scored using
the values sets for England. This data will also be con-
verted into QALYs using the under the curve approach.
The QALYs which are calculated for the carers will be
included as part of the cost-consequence analysis. Fur-
ther consequences will be examined as part of the cost
consequences analysis including primary and secondary
clinical outcomes, particularly the health-related quality
of life of the child and their care-giver. These will in-
clude benefits which cannot be included with the scope
of the QALY outcome.
Analysis
For the cost-effectiveness analysis, an incremental cost
per unit change in the CGI-I scale will be calculated,
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with the aim of calculating the cost for achieving a min-
imally important difference in the CGI-I. Point estimates
of costs and effects, cost effect plots and acceptability
curves will be produced. Statistical imprecision and un-
certainty will be examined using a stochastic sensitivity
analysis. The cost-utility analysis will be analysed in a
similar way, to the cost-effectiveness analysis. A formal
decision analytic model is not currently planned but
may be used if the cost of the intervention is not offset
by a reduction in resource use or gain in QALYs for the
child. If the results are conclusive (i.e. the intervention
more effective and less costly or less effective and more
costly) then a model will not be required.
The cost-consequence analysis will present the costs
and consequences as a difference between randomised
groups with appropriate measures of variance.
Monitoring
Data monitoring and ethics committee
The project has a Trial Steering Committee (TSC) inde-
pendently chaired by Professor Patricia Howlin (Emiritus
Professor of Clinical Child Psychology) and is comprised
of a panel of independent members including a Statisti-
cian, Health Economist and two Parent Representatives
as well as Non-Independent members that form the
Trial Management Group (TMG). The Data Monitoring
Committee (DMC) is independently chaired by Professor
John Jerrim (Professor of Education and Social Statistics)
and comprised of a panel of Independent members
including a Principal Clinical Psychologist and Post-
Doctoral Research Associate as well as Non-Independent
members that are part of the Trial Management Group.
Serious adverse events, and actions taken, will be logged
by the senior trial manager (CTU) or trial manager (CTU)
and a report presented to DMC. The DMEC is independ-
ent of sponsor and funder and declares no competing in-
terests. Further details of the DMEC charter are available
from the trial manager.
Recording and reporting AEs and SAEs For the
purposes of this trial, only serious adverse events
(adverse events which meet the criteria for seriousness)
will be captured for the parent/carer and child partici-
pants. Serious adverse events will be captured from the
start date of intervention until the follow-up assessment
at week 24.
Events of special interest As well as collecting and en-
suring SAEs are reported, events of special interest will
also be collected. An event of special interest is any
event relating to child wellbeing and family/life difficul-
ties which is not expected and not anticipated in ‘normal
day-to-day life’, but is not a physical medical event.
Events of special interest will be recorded for both the
parent and child participants from the start date of the
intervention until the follow-up assessment at week 24.
Dissemination
The dissemination strategy for this research will include
several complementary strands of activity. We will work
closely with parents and the autism community to
ensure that the results are interpreted and reported in a
meaningful way: The results of the study will be shared
as follows:
1. Local dissemination at each site including parent
newsletters
2. Wider national and international dissemination
including conferences and publications
3. NHS Clinicians and Commissioners events to
discuss the implications of the research
Discussion
The design will take a rigorous scientific approach by
utilising a three-site, two-group randomised controlled
design comparing two active parent group interventions.
This study will evaluate the clinical and cost-
effectiveness of the Managing Repetitive Behaviours
(MRB) parent group intervention compared with the
Learning About Autism psychoeducation parent group.
The Learning About Autism (LAA) parent group, deliv-
ered by staff trained by The National Autistic Society,
and equivalent to best current practice, allows us to con-
trol for the non-specific social group benefit of mutual
sharing of experience and support between parents.
Parent group based interventions provide opportun-
ities for mutual learning and sharing of ideas, allowing
parents to discuss how best to support their child’s
development. This fosters opportunities for parents to
learn from and support each other, in turn building par-
ents’ knowledge and confidence to support their child’s
needs. However, in our MRB parent group intervention,
we have included targeted support on challenging re-
stricted and repetitive behaviours that are interfering in
a deleterious way for the child. There is some informa-
tion on restricted and repetitive behaviours in the LAA
parent group but MRB focuses more on assisting parents
to understand the role that RRB may have in their autis-
tic child’s life. In this way, we anticipate that MRB will
have a greater beneficial effect on reducing identified
challenging RRB and improving child overall wellbeing.
Moreover, we will evaluate whether providing parents
with the skills to effectively understand their child’s chal-
lenging RRB has a greater effect on parental wellbeing,
sense of competence, reducing stress and improving
family cohesion than a general autism psychoeducation
parent group. In this way, the results from this RCT
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have the potential to help autism researchers explore the
active ingredients of clinical trials.
We have carefully considered in collaboration with par-
ents and professionals the utility of the outcome measures
chosen to assess the effects of the intervention on challen-
ging RRB, overall child functioning and parent and family
wellbeing. We have taken a rigorous approach to outcome
assessment with independent objective measures, where
possible. We are aware of limitations in autism research
from over reliance on unblinded parental report measures
and have therefore included other outcome measures such
as teacher-rated outcomes.
If found to be effective and efficient in the proposed
evaluation study, this early parent group based intervention
targeting challenging RRB has the potential to fill an identi-
fied but unmet need and thus improve the wellbeing of
autistic children and their families, reduce parental stress,
greatly enhance community participation, increase learning
opportunities and improve longer-term outcomes.
COVID-19 addendum
Following the announcement from the government on
23rd March 2020 in response to the COVID-19 pandemic,
a strict UK lockdown was imposed, with implications for
all clinical services and research trials across the UK. For
our Managing Repetitive Behaviours (MRB) randomised
controlled trial (RCT) this has meant a great deal of in-
novative creative thinking to design a revised research
protocol for the conduct of all aspects of the research and
the delivery of the two parent group based interventions.
The aim was to ensure that recruited families and all the
clinical and research staff were safe and that all our proce-
dures were compliant with national government guidance
documents and the required health and safety recommen-
dations and procedures from the National Institute for
Health Research (NIHR) and the Department of Health.
With support from the research sponsor and funder an
agreed plan to do assessments remotely, and run parent
groups online was made.
A key priority for our clinical research team was to
continue to keep the study open, to maintain as best as
we could the integrity of the study and retain recruited
families to the end of the trial despite the restrictions
imposed by the COVID-19 pandemic. We are aware that
families of autistic children are facing additional chal-
lenges in light of COVID-19 with reduced access to sup-
port and services. This was an added reason to remain
in contact with families recruited to our study. We heard
from parents that many children are finding changes to
their usual routines very challenging and that there was
a disproportionate impact on families caring for autistic
children. This is important information that may impact
on the conduct and results of this RCT. For all these
reasons we were very keen to keep in touch with our
recruited families for the duration of these challenging
times. However, we also needed to take proactive pre-
cautions to protect the health of all the families in the
trial and our staff in line with recommendations from
the government, NHS and NIHR and comply with local
site restrictions, which varied between sites. The trial
team have worked with all sites, sponsor and funder to
ensure the most appropriate actions have been taken.
The Trial Management Group with sponsor support on
26th March 2020, agreed all study activities would be
performed remotely by sites wherever possible. Following
this, we implemented non-substantial amendment 08
(NS08) on 3rd April 2020 as sponsor category C to reflect
remote working changes with protocol version 06.
COVID-19 remote working measures
1. Study Research Associates (RA) are now working
remotely at home in line with local policies
following government advice and restrictions.
Investigative site files have been re-located to
clinical sites wherever possible; however, access to
these and any paper source documents is now
either limited or not possible at this time.
a. RAs working remotely at home must have
access to secure laptops, which connect to the
University/NHS server as appropriate. Phone
calls to parents can be made at home but no
patient identifiable data can be stored in homes.
b. All new paper source documents, including any
RA notes, will either be recorded electronically
for this period of time so that no patient details
are stored outside of the local site server, or
written on paper copies with no participant
Identifiable data (PID) where applicable.
c. Remote supervision of RAs to be arranged at
each site, with local principle investigator (PI)
oversight, and documented.
2. Ongoing review of the situation and ability to
remain open to any study activities
a. Sites to inform Chief Investigator (CI) and
Newcastle Clinical Trial Unit (NCTU) of any
changes in availability of staffing at each site
b. Study recruitment should be halted at individual
site level if sites are no longer able to deliver the
study. An amendment will only be submitted if
the study is halted at sponsor level as discussed
with the CI and NCTU.
c. To consider availability of the CI to provide
central study advice.
d. The NCTU will inform sites of any overall study
halt. It is then the responsibility of the local
clinical team to risk assess participants that are
already in the study.
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A suite of documents including a contingency plan and
working instruction have been created to aid all sites in
the day to day workings of the study and remote working
procedures. A sponsor specific contingency document has
also been created to ensure sponsor is kept up to date with
all the changes put in place. Furthermore, any future
changes to the study relating to COVID-19 will be
reviewed in line with the government guidance updates.
Intervention parent groups
We have explored digital options with our NHS clinical
colleagues at each of the three sites to identify a secure
and reliable platform that allows us to deliver our parent
groups online. It was important the technology was easy
to use for parents and group leaders, but still allowed
group leaders to present information and participate in
group chat with families.
For some families, attending online parent groups has
been an easier option for them to consider as it has re-
moved some of the barriers such as geographical, trans-
port, work or other commitments that had previously
prevented them from attending a parent group. We are
mindful of issues of digital poverty but initial feedback
from families has been positive, and most families have
been able to join a parent group using a range of devices
such as smart phones, tablets or computer.
Trial status
Protocol Version 6.0; approval date: 02/04/2020.
The trial is recruiting. Recruitment began on the
following dates for each site:
CNTW 02/10/2018; Lothian 20/11/2018; TEWV 22/
11/2018.
Recruitment is due to complete on the 31/08/2020.
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